Soy Isoflavones Investigated in Phase II Trial for Recurrent Prostate Cancer or Rising PSA

Recurrence of prostate cancer and rising prostate-specific antigen (PSA) levels are critical concerns for patients post-treatment, often indicating disease progression. Current standard-of-care options can have significant side effects, driving interest in complementary approaches. Epidemiological studies suggest that diets high in soy foods may reduce the risk of certain cancers, including prostate cancer. Isoflavones, the active compounds in soy, are hypothesized to exert anti-cancer effects, making them a promising candidate for therapeutic investigation in this patient population.

This study is a randomized phase II trial designed to evaluate the efficacy of soy isoflavones in patients diagnosed with recurrent prostate cancer or experiencing a rise in prostate-specific antigen (PSA). The trial aims to determine how well soy isoflavones work as a treatment. Specific details regarding the dose, route, frequency, and duration of the soy isoflavone intervention, as well as the exact number of participants (n) and the nature of the control arm (e.g., placebo or active comparator), are not provided in this abstract describing the trial's purpose.

This abstract describes the rationale and purpose of a clinical trial, not its findings. As such, no results regarding the efficacy or safety of soy isoflavones in treating recurrent prostate cancer or rising prostate-specific antigen are presented. The trial is designed to investigate these outcomes, but the data collection and analysis are either ongoing or have not yet been published. Therefore, no specific numbers, p-values, or fold-changes related to patient outcomes or biological pathways (PSA, androgen receptor) can be reported at this time.